<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01189240</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-02509</org_study_id>
    <secondary_id>NCI-2011-02509</secondary_id>
    <secondary_id>CDR0000683099</secondary_id>
    <secondary_id>ABTC-1002</secondary_id>
    <secondary_id>ABTC-1002</secondary_id>
    <secondary_id>U01CA137443</secondary_id>
    <nct_id>NCT01189240</nct_id>
  </id_info>
  <brief_title>RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma</brief_title>
  <official_title>Phase I/II Study of R04929097 With Bevacizumab in Patients With Recurrent Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial is studying the side effects and the best dose of RO4929097 to see how
      well it works when given together with bevacizumab compared to bevacizumab alone in treating
      patients with progressive or recurrent malignant glioma. RO4929097 may stop the growth of
      tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies,
      such as bevacizumab, can block tumor growth in different ways. Some block the ability of
      tumor cells to grow and spread. Others find tumor cells and help kill them or carry
      tumor-killing substances to them. Giving RO4929097 together with bevacizumab may kill more
      tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I

      Primary Objective:

        1. To assess the safety profile of R04929097 in combination with bevacizumab and to
           determine a recommended Phase II dose of R04929097 in combination with bevacizumab in
           patients with recurrent malignant glioma

           Secondary Objectives:

        2. To describe the toxicity associated with this combination regimen

        3. To assess pharmacokinetics of R04929097 in combination with bevacizumab

      Phase II I. Assess the safety profile and the recommended phase II dose of gamma-secretase
      inhibitor RO4929097 (RO4929097) in combination with bevacizumab in patients with recurrent
      malignant glioma.

      II. Assess the progression-free survival at 6 months of patients treated with this regimen.

      III. Compare the overall survival of patients with recurrent glioblastoma treated with
      RO4929097 and bevacizumab versus bevacizumab alone.

      SECONDARY OBJECTIVES:

      I. Describe the toxicity associated with this regimen in these patients. II. Assess the
      pharmacokinetics of this regimen in these patients. III. Estimate the proportion of patients
      alive and progression-free survival at 6 months in patients treated with RO4929097 and
      bevacizumab versus bevacizumab alone.

      IV. Evaluate the safety and tolerability of these regimens in these patients. V. Explore
      potential prognostic biomarkers from glioma tissue at baseline and potential association with
      Notch pathway inhibition.

      OUTLINE: This is a multicenter, phase I, dose-escalation study of gamma-secretase inhibitor
      RO4929097 (RO4929097) followed by a randomized phase II study.

      PHASE I: Patients receive oral RO4929097 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab
      IV over 30-90 minutes on days 1 and 15 (days 2 or 3 and 15 of course 1 only). Courses repeat
      every 28 days in the absence of disease progression or unacceptable toxicity.

      PHASE II: Patients are randomized* to 1 of 2 treatment arms.

      ARM I: Patients receive oral RO4929097 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab
      IV over 30-90 minutes on days 1 and 15.

      ARM II: Patients receive bevacizumab as in arm I.

      In both arms, courses repeat every 28 days in the absence of disease progression or
      unacceptable toxicity.

      NOTE: *If phase II single-arm study demonstrates effectiveness, it will proceed to the phase
      II randomized study.

      Some patients undergo blood sample collection for pharmacokinetic studies. Archived tumor
      tissue samples are analyzed for potential biomarkers and Notch pathway inhibition.

      After completion of study therapy, patients are followed up every 2 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company decided to stop development of drug - 7/31/12
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated Dose and the Recommended Phase II Dose of Gamma-secretase Inhibitor RO4929097 in Combination With Bevacizumab Determined by Dose-limiting Toxicity Rate (Phase I)</measure>
    <time_frame>28 days</time_frame>
    <description>Pts were treated at escalating dose levels of RO4929097 (Dose levels: 5, 10 or 20 mg) for an observed evaluation at the end of a 4week period. 3 pts treated at each cohort if less than or equal to 33% dose will be escalated. Pts must receive one dose of treatment to be evaluated for toxicity. A standard 3+3 dose escalation method will be used</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity Description (Dose Limiting Toxicity-DLT) of Gamma-secretase Inhibitor RO4929097 in Combination With Bevacizumab</measure>
    <time_frame>28 days - 1 cycle</time_frame>
    <description>Pts were treated at escalating dose levels of RO4929097 (Dose levels: 5, 10 or 20 mg) for an observed evaluation at the end of a 4week period. 3 pts treated at each cohort. Pts must receive one dose of treatment to be evaluated for toxicity. Toxcity description associated with combination of RO4929097 and Bevacizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Cmax to Determine the Effect of Bevacizumab on the Plasma Pharmacokinetics of RO4929097 Day 1</measure>
    <time_frame>24 hrs</time_frame>
    <description>all pts at all dose levels (5,10 and 20mg) will have pks collected. 10 samples will be collected at various time points over a 24 hour time point. Samples will be collected on the first day of treatment during cycle 1.
For initial cycle (Cycle 1) bevacizumab was not given until 2 or 3 days after all PKs samples of initial dose of RO49290977 was collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Cmax to Determine the Effect of Bevacizumab on the Plasma Pharmacokinetics of RO4929097 Day 15</measure>
    <time_frame>24hr</time_frame>
    <description>all pts at all dose levels (5,10 and 20mg) will have pks collected. 10 samples will be collected at various time points over a 24 hour time point. Samples will be collected on the 15th day of treatment during cycle 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of AUC24 to Determine the Effect of Bevacizumab on the Plasma Pharmacokinetics of RO4929097 Day 1</measure>
    <time_frame>24hrs</time_frame>
    <description>all pts at all dose levels (5,10 and 20mg) will have pks collected. 10 samples will be collected at various time points over a 24 hour time point. Samples will be collected on the first day of treatment during cycle 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of AUC24 to Determine the Effect of Bevacizumab on the Plasma Pharmacokinetics of RO4929097 Day 15</measure>
    <time_frame>24hr</time_frame>
    <description>all pts at all dose levels (5,10 and 20mg) will have pks collected. 10 samples will be collected at various time points over a 24 hour time point. Samples will be collected on the 15th day of treatment during cycle 1.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Adult Anaplastic Astrocytoma</condition>
  <condition>Adult Anaplastic Oligodendroglioma</condition>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Recurrent Adult Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Phase I Dose Finding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II Stage I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15.Other: laboratory biomarker analysis: correlative studies.
Phase 2 - not implemented due to drug supply from company</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II Stage II Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: laboratory biomarker analysis: correlative studies.
Phase 2 - not implemented due to drug supply from company</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II Stage II Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Other: laboratory biomarker analysis: correlative studies.
Phase 2 - not implemented due to drug supply from company</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I Dose Finding - Level 1 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 5mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I Dose Finding - Level 2 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 10mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I Dose Finding - Level 3 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 20mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gamma-secretase/Notch signalling pathway inhibitor RO4929097</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Phase I Dose Finding</arm_group_label>
    <arm_group_label>Phase II Stage I</arm_group_label>
    <arm_group_label>Phase II Stage II Arm 1</arm_group_label>
    <arm_group_label>Phase I Dose Finding - Level 1 5mg</arm_group_label>
    <arm_group_label>Phase I Dose Finding - Level 2 10mg</arm_group_label>
    <arm_group_label>Phase I Dose Finding - Level 3 20mg</arm_group_label>
    <other_name>R4733</other_name>
    <other_name>RO4929097</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Phase I Dose Finding</arm_group_label>
    <arm_group_label>Phase II Stage I</arm_group_label>
    <arm_group_label>Phase II Stage II Arm 1</arm_group_label>
    <arm_group_label>Phase II Stage II Arm 2</arm_group_label>
    <arm_group_label>Phase I Dose Finding - Level 1 5mg</arm_group_label>
    <arm_group_label>Phase I Dose Finding - Level 2 10mg</arm_group_label>
    <arm_group_label>Phase I Dose Finding - Level 3 20mg</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>Avastin</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Phase I Dose Finding</arm_group_label>
    <arm_group_label>Phase II Stage I</arm_group_label>
    <arm_group_label>Phase II Stage II Arm 1</arm_group_label>
    <arm_group_label>Phase II Stage II Arm 2</arm_group_label>
    <arm_group_label>Phase I Dose Finding - Level 1 5mg</arm_group_label>
    <arm_group_label>Phase I Dose Finding - Level 2 10mg</arm_group_label>
    <arm_group_label>Phase I Dose Finding - Level 3 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Phase I Dose Finding</arm_group_label>
    <arm_group_label>Phase I Dose Finding - Level 1 5mg</arm_group_label>
    <arm_group_label>Phase I Dose Finding - Level 2 10mg</arm_group_label>
    <arm_group_label>Phase I Dose Finding - Level 3 20mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed malignant glioma (phase I)

               -  Glioblastoma

               -  Anaplastic astrocytoma

               -  Anaplastic oligodendroglioma

               -  Mixed anaplastic oligoastrocytoma

          -  Histologically confirmed glioblastoma following radiotherapy and temozolomide (phase
             II)

          -  Progressive or recurrent disease after conformal external-beam radiation therapy and
             concurrent temozolomide, followed by ≥ 1 adjuvant course of temozolomide

          -  Measurable disease by MRI within the past 2 weeks

          -  Tumor tissue form indicating availability of archived tissue from initial resection at
             diagnosis of malignant glioma completed and signed by a pathologist

          -  Karnofsky performance status 60-100%

          -  ANC ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 9 g/dL

          -  Total bilirubin normal

          -  AST and ALT ≤ 2.5 times upper limit of normal

          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min

               -  Urine protein: If proteinuria ≥ +2 protein, a protein level should be &lt; 1,000 mg
                  by a 24-hour urine collection

          -  Electrolytes (calcium, chloride, magnesium, potassium, phosphorus, sodium) within
             institutional normal limits

          -  Fertile patients must use 2 forms of effective contraception before, during, and for ≥
             12 months (6 months phase II, bevacizumab arm only) after treatment

          -  Negative pregnancy test

          -  Not pregnant or nursing

          -  At least 5 years since prior malignancy except nonmelanoma skin cancer, or carcinoma
             in situ of the cervix, breast, or bladder

          -  Mini Mental State Exam score of ≥ 15

          -  Must be able to tolerate MRI

        Exclusion Criteria:

          -  No serious concurrent infection or medical illness that would jeopardize the ability
             of the patient to receive the treatment outline in this protocol with reasonable
             safety

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biological composition to gamma-secretase inhibitor RO4929097 or bevacizumab

          -  Must be able to swallow capsules

          -  No malabsorption syndrome or other condition that would interfere with intestinal
             absorption

          -  No baseline QTcF &gt; 450 msec (male) or QTcF &gt; 470 msec (female)

          -  Not history of being serologically positive for hepatitis A, B, or C

          -  No history of cirrhosis

          -  No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, or hypokalemia despite
             adequate electrolyte supplementation

          -  No uncontrolled intercurrent illness including, but not limited to, any of the
             following:

               -  Ongoing or active infection

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  A history of torsades de pointes or other significant cardiac arrhythmias other
                  than chronic, stable atrial fibrillation

               -  Psychiatric illness and/or social situations that would limit compliance with
                  study requirements

          -  No serious or non-healing wound, ulcer, or bone fracture

          -  No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal
             abscess within the past 6 months

          -  No significant vascular disease (e.g., aortic aneurysm requiring surgical repair or
             recent peripheral arterial thrombosis) within the past 6 months

          -  No clinically significant cardiovascular disease, including any of the following:

               -  Inadequately controlled hypertension (systolic BP &gt; 160 mm Hg and/or diastolic BP
                  &gt; 90 mm Hg) despite antihypertensive medication

               -  History of cerebrovascular accident or transient ischemic attack at any time

               -  Myocardial infarction or unstable angina within the past 12 months

               -  NYHA grade II-IV congestive heart failure

               -  Serious and inadequately controlled cardiac arrhythmia

               -  Significant vascular disease (e.g., aortic aneurysm or history of aortic
                  dissection)

               -  Clinically significant peripheral vascular disease

          -  No evidence of bleeding diathesis or coagulopathy

          -  No known hypersensitivity to Chinese hamster ovary cell products or other recombinant
             human antibodies

          -  No requirement for antiarrhythmics or other medications known to prolong QTc

          -  One or 2 prior treatment regimens allowed

          -  Recovered from severe toxicity of prior therapy

          -  At least 3 months since prior radiotherapy

          -  At least 6 weeks since prior nitrosourea

          -  At least 3 weeks since prior chemotherapy

          -  At least 4 weeks since prior and no other concurrent investigational agents

          -  At least 2 weeks since prior non-cytotoxic, FDA-approved agent (e.g., Tarceva
             [erlotinib hydrochloride], hydroxychloroquine, bevacizumab, etc.)

          -  At least 28 days since any prior surgery

          -  No prior γ-secretase inhibitors and/or bevacizumab

          -  At least 10 days since prior and no concurrent enzyme-inducing anti-epileptic drug

          -  No concurrent combination antiretroviral therapy for HIV-positive patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Pan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at Los Angeles (UCLA )</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Medical Center-Parnassus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2010</study_first_submitted>
  <study_first_submitted_qc>August 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2010</study_first_posted>
  <results_first_submitted>May 5, 2015</results_first_submitted>
  <results_first_submitted_qc>June 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 14, 2015</results_first_posted>
  <last_update_submitted>November 13, 2015</last_update_submitted>
  <last_update_submitted_qc>November 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase I trial started 8/2011 and enrollment closed 7/31/12. 13 total patients treated by RO4929097 (5, 10, 20mg/kg) in combo with bevacizumab. 1 treated pt ineligible for study. Analysis data for toxicity included 13 treated pts. Analytical dataset results other than toxicity included 12 eligible pts only. Pts enrolled from outpt medical clinics</recruitment_details>
      <pre_assignment_details>A decision was made from the company, Roche, the owner and developer of RO4929097, that as of 7/31/12 there would be no further supply of RO4929097 and all clinical trials using this drug must stop accruing and treating patients. Hence our ABTC 1002 study was stopped during the phase 1 with 13 pt accrued and the Phase 2 was unable to begin.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I Dose Finding - Level 1 5mg</title>
          <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 5mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
        </group>
        <group group_id="P2">
          <title>Phase I Dose Finding Level 2 10mg</title>
          <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 10mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
        </group>
        <group group_id="P3">
          <title>Phase I Dose Finding Level 3 20mg</title>
          <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 20mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>1 pt not eligible for study and hence was not included in the analytical analysis</population>
      <group_list>
        <group group_id="B1">
          <title>Phase I Dose Finding</title>
          <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="42" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status</title>
          <description>100-80: Able to carry on normal activity and to work; No special care needed.
70-50: Unable to work; able to live at home and care for most personal needs; varying amount of assistance needed.
40-10: Unable to care for self; Requires equivalent of institutional or hospital care;diseases may be progressing rapidly.
0: Dead</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mini Mental State Examination (MMSE)</title>
          <description>Measure of Cognitive impairment
24-30 No cognitive impairment 18-23 Mild cognitive impairment 0-17 Severe cognitive impairment
Series of questions with a point value for each question which is summed to give a total final score.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" lower_limit="21" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Relapses</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1 relapse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 relapes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 relapses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Initial Procedure</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>biopsy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Initial Histological Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Glioblastoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum-tolerated Dose and the Recommended Phase II Dose of Gamma-secretase Inhibitor RO4929097 in Combination With Bevacizumab Determined by Dose-limiting Toxicity Rate (Phase I)</title>
        <description>Pts were treated at escalating dose levels of RO4929097 (Dose levels: 5, 10 or 20 mg) for an observed evaluation at the end of a 4week period. 3 pts treated at each cohort if less than or equal to 33% dose will be escalated. Pts must receive one dose of treatment to be evaluated for toxicity. A standard 3+3 dose escalation method will be used</description>
        <time_frame>28 days</time_frame>
        <population>RO4929097 Days 1-3 weekly (doses 5,10, 20 mg) + Bev 10mg/kg IV q2 wks - cycle 28 days. 3+3 dose escalation method will be used. Target DLT is &gt; or equal to 33%</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I Dose Finding</title>
            <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum-tolerated Dose and the Recommended Phase II Dose of Gamma-secretase Inhibitor RO4929097 in Combination With Bevacizumab Determined by Dose-limiting Toxicity Rate (Phase I)</title>
          <description>Pts were treated at escalating dose levels of RO4929097 (Dose levels: 5, 10 or 20 mg) for an observed evaluation at the end of a 4week period. 3 pts treated at each cohort if less than or equal to 33% dose will be escalated. Pts must receive one dose of treatment to be evaluated for toxicity. A standard 3+3 dose escalation method will be used</description>
          <population>RO4929097 Days 1-3 weekly (doses 5,10, 20 mg) + Bev 10mg/kg IV q2 wks - cycle 28 days. 3+3 dose escalation method will be used. Target DLT is &gt; or equal to 33%</population>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity Description (Dose Limiting Toxicity-DLT) of Gamma-secretase Inhibitor RO4929097 in Combination With Bevacizumab</title>
        <description>Pts were treated at escalating dose levels of RO4929097 (Dose levels: 5, 10 or 20 mg) for an observed evaluation at the end of a 4week period. 3 pts treated at each cohort. Pts must receive one dose of treatment to be evaluated for toxicity. Toxcity description associated with combination of RO4929097 and Bevacizumab</description>
        <time_frame>28 days - 1 cycle</time_frame>
        <population>DLT Defintion, must be related to RO and/or Bev: ANC &lt;/= 500/μL or second time ANC &lt;1,000/μL; PLTs &lt;/= 25,000/μL or second time platelets &lt;50,000/μL; Febrile neutropenia;Thrombocytopenic bleeding (platelets &lt;50,000/μL and with clinically significant bleeding); Delay of treatment &gt; 14 days ;grade 3 or 4 non-hematological toxicity (some exceptions)</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I Dose Finding - Level 1 5mg</title>
            <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 5mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Phase I Dose Finding Level 2 10mg</title>
            <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 10mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Phase I Dose Finding Level 3 20mg</title>
            <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 20mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity Description (Dose Limiting Toxicity-DLT) of Gamma-secretase Inhibitor RO4929097 in Combination With Bevacizumab</title>
          <description>Pts were treated at escalating dose levels of RO4929097 (Dose levels: 5, 10 or 20 mg) for an observed evaluation at the end of a 4week period. 3 pts treated at each cohort. Pts must receive one dose of treatment to be evaluated for toxicity. Toxcity description associated with combination of RO4929097 and Bevacizumab</description>
          <population>DLT Defintion, must be related to RO and/or Bev: ANC &lt;/= 500/μL or second time ANC &lt;1,000/μL; PLTs &lt;/= 25,000/μL or second time platelets &lt;50,000/μL; Febrile neutropenia;Thrombocytopenic bleeding (platelets &lt;50,000/μL and with clinically significant bleeding); Delay of treatment &gt; 14 days ;grade 3 or 4 non-hematological toxicity (some exceptions)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Cmax to Determine the Effect of Bevacizumab on the Plasma Pharmacokinetics of RO4929097 Day 1</title>
        <description>all pts at all dose levels (5,10 and 20mg) will have pks collected. 10 samples will be collected at various time points over a 24 hour time point. Samples will be collected on the first day of treatment during cycle 1.
For initial cycle (Cycle 1) bevacizumab was not given until 2 or 3 days after all PKs samples of initial dose of RO49290977 was collected</description>
        <time_frame>24 hrs</time_frame>
        <population>Day One only</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I Dose Finding - Level 1 5mg</title>
            <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 5mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
For initial cycle (Cycle 1) bevacizumab was not given until 2 or 3 days after all PKs samples of initial dose of RO49290977 was collected
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Phase I Dose Finding Level 2 10mg</title>
            <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 10mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
For initial cycle (Cycle 1) bevacizumab was not given until 2 or 3 days after all PKs samples of initial dose of RO49290977 was collected
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Phase I Dose Finding Level 3 20mg</title>
            <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 20mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
For initial cycle (Cycle 1) bevacizumab was not given until 2 or 3 days after all PKs samples of initial dose of RO49290977 was collected
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Cmax to Determine the Effect of Bevacizumab on the Plasma Pharmacokinetics of RO4929097 Day 1</title>
          <description>all pts at all dose levels (5,10 and 20mg) will have pks collected. 10 samples will be collected at various time points over a 24 hour time point. Samples will be collected on the first day of treatment during cycle 1.
For initial cycle (Cycle 1) bevacizumab was not given until 2 or 3 days after all PKs samples of initial dose of RO49290977 was collected</description>
          <population>Day One only</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129" spread="41"/>
                    <measurement group_id="O2" value="177" spread="32"/>
                    <measurement group_id="O3" value="241" spread="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Cmax to Determine the Effect of Bevacizumab on the Plasma Pharmacokinetics of RO4929097 Day 15</title>
        <description>all pts at all dose levels (5,10 and 20mg) will have pks collected. 10 samples will be collected at various time points over a 24 hour time point. Samples will be collected on the 15th day of treatment during cycle 1.</description>
        <time_frame>24hr</time_frame>
        <population>Day 15 only. Level 2 10mg only had 5pts with evaluable PKs at day 15</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I Dose Finding - Level 1 5mg</title>
            <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 5mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Phase I Dose Finding Level 2 10mg</title>
            <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 10mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Phase I Dose Finding Level 3 20mg</title>
            <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 20mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Cmax to Determine the Effect of Bevacizumab on the Plasma Pharmacokinetics of RO4929097 Day 15</title>
          <description>all pts at all dose levels (5,10 and 20mg) will have pks collected. 10 samples will be collected at various time points over a 24 hour time point. Samples will be collected on the 15th day of treatment during cycle 1.</description>
          <population>Day 15 only. Level 2 10mg only had 5pts with evaluable PKs at day 15</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" spread="37"/>
                    <measurement group_id="O2" value="189" spread="49"/>
                    <measurement group_id="O3" value="245" spread="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of AUC24 to Determine the Effect of Bevacizumab on the Plasma Pharmacokinetics of RO4929097 Day 1</title>
        <description>all pts at all dose levels (5,10 and 20mg) will have pks collected. 10 samples will be collected at various time points over a 24 hour time point. Samples will be collected on the first day of treatment during cycle 1.</description>
        <time_frame>24hrs</time_frame>
        <population>Day 1</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I Dose Finding - Level 1 5mg</title>
            <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 5mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
For initial cycle (Cycle 1) bevacizumab was not given until 2 or 3 days after all PKs samples of initial dose of RO49290977 was collected
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Phase I Dose Finding Level 2 10mg</title>
            <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 10mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
For initial cycle (Cycle 1) bevacizumab was not given until 2 or 3 days after all PKs samples of initial dose of RO49290977 was collected
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Phase I Dose Finding Level 3 20mg</title>
            <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 20mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
For initial cycle (Cycle 1) bevacizumab was not given until 2 or 3 days after all PKs samples of initial dose of RO49290977 was collected
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of AUC24 to Determine the Effect of Bevacizumab on the Plasma Pharmacokinetics of RO4929097 Day 1</title>
          <description>all pts at all dose levels (5,10 and 20mg) will have pks collected. 10 samples will be collected at various time points over a 24 hour time point. Samples will be collected on the first day of treatment during cycle 1.</description>
          <population>Day 1</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1,215" spread="361"/>
                    <measurement group_id="O2" value="2,385" spread="606"/>
                    <measurement group_id="O3" value="2,232" spread="781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of AUC24 to Determine the Effect of Bevacizumab on the Plasma Pharmacokinetics of RO4929097 Day 15</title>
        <description>all pts at all dose levels (5,10 and 20mg) will have pks collected. 10 samples will be collected at various time points over a 24 hour time point. Samples will be collected on the 15th day of treatment during cycle 1.</description>
        <time_frame>24hr</time_frame>
        <population>Day 15. Only 4 pts samples were evaluable for AUC 24 at the10mg dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I Dose Finding - Level 1 5mg</title>
            <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 5mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Phase I Dose Finding Level 2 10mg</title>
            <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 10mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Phase I Dose Finding Level 3 20mg</title>
            <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 20mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of AUC24 to Determine the Effect of Bevacizumab on the Plasma Pharmacokinetics of RO4929097 Day 15</title>
          <description>all pts at all dose levels (5,10 and 20mg) will have pks collected. 10 samples will be collected at various time points over a 24 hour time point. Samples will be collected on the 15th day of treatment during cycle 1.</description>
          <population>Day 15. Only 4 pts samples were evaluable for AUC 24 at the10mg dose.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1,212" spread="355"/>
                    <measurement group_id="O2" value="2,351" spread="1,071"/>
                    <measurement group_id="O3" value="2,555" spread="1,363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose of drug, than weekly during cycle 1 and then once every 28 days until disease progression, approximately 1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase I Dose Finding</title>
          <description>Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.
gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orally
bevacizumab: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sigmoidectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>dyspagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>mucositis oral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>edema limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>alkaline phosphatase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>aspartate aminotransferase increase</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>blood bilirubin increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>neutrophil count decrease</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>platelet count decrease</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>white blood cells decrease</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dysphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>headaches</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>irregular menstruation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>voice alteration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>alopecia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is Phase 1/Phase 2 Study. It closed prematurely by Roche, study still in Phase 1. Roche halted pt enrollment in ALL clinical trials w/ RO4929097 &amp; cease production of drug &amp; development. Phase 2 of this study was never activated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Edward Pan</name_or_title>
      <organization>Adult Brain Tumor Consortium (ABTC)</organization>
      <email>Edward.Pan@UTSouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

